Normal view MARC view ISBD view

Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects. [electronic resource]

By:

Gardin, Anne

Contributor(s):

Producer: 20190308Description: 1593-1604 p. digitalISSN:

1432-1041

Subject(s):

Online resources:

Available from publisher's website

In: European journal of clinical pharmacology vol. 74

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

to post a comment.

Back to results

3541 The state of pharmacotherapy for the treatment of alcohol dependence.
by Garbutt, James C
3542 Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment.
by Stoops, William W
3543 Medications for adolescents and young adults with autism spectrum disorders: a systematic review.
by Dove, Dwayne
3544 Dissociable effects of ultralow-dose naltrexone on tolerance to the antinociceptive and cataleptic effects of morphine.
by Tuerke, Katharine J
3545 Urge-specific and lifestyle coping strategies of alcoholics: relationships of specific strategies to treatment outcome.
by Dolan, Sara L
3546 Specific and nonspecific effects of naltrexone on goal-directed and habitual models of alcohol seeking and drinking.
by Hay, Rachel A
3547 Investigation of 7-benzylidenenaltrexone derivatives as a novel structural antitrichomonal lead compound.
by Kutsumura, Noriki
3548 Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety.
by O'Malley, Stephanie S
3549 Effectiveness of alcohol treatment interventions integrated into routine tuberculosis care in Tomsk, Russia.
by Shin, Sonya
3550 A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers.
by Silverman, Bernard L
3551 Acceptability and feasibility of a randomized clinical trial of oral naltrexone vs. placebo for women living with HIV infection: Study design challenges and pilot study results.
by Cook, Robert L
3552 Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder.
by Murphy, Sean M
3553 Role of mu, but not delta or kappa, opioid receptors in context-induced reinstatement of oxycodone seeking.
by Bossert, Jennifer M
3554 Use of drugs for alcohol use disorder in Norway 2004–16.
by Heldal, Anne Taraldsen
3555 Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder.
by Klemperer, Elias M
3556 Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet.
by Sun, Lei
3557 Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial.
by Roche, Daniel J O
3558 Opiate receptor agonists as modulators of gamma-aminobutyric acid turnover in the nucleus caudatus, globus pallidus and substantia nigra of the rat.
by Moroni, F
3559 Antagonism of morphine antinociception by intrathecally administered corticotropin-releasing factor in mice.
by Song, Z H
3560 Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone.
by Kosten, T R